Islet Sciences, Inc., (ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Japanese Patent for allowed claims, Patent Application No. 2008-529208.
“This patent is another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community and our stakeholders,” said John Steel, Chairman and CEO of Islet Sciences. “We are pleased to announce this significant milestone which clearly strengthens our global value proposition. This patent provides further evidence for the value and promise of this technology to be developed for treatments for diabetes and related complications.”
The notice of allowed claims includes the use and composition for small molecules for prevention or treatment of a pathological inflammatory or autoimmune condition. In particular the pathological conditions include Type 1 diabetes, atherosclerosis, type 2 diabetes, disorders associated with visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer's disease.
About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti inflammatory compounds. For more information: www.isletsciences.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.